TY - JOUR
T1 - The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early‐Stage Hepatocellular Carcinoma after Curative Treatment
AU - Bae, Bong Kyung
AU - Park, Hee Chul
AU - Yoo, Gyu Sang
AU - Choi, Moon Seok
AU - Oh, Joo Hyun
AU - Yu, Jeong Il
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Systemic inflammatory markers (SIMs) are known to be associated with carcinogenesis and prognosis of hepatocellular carcinoma (HCC). We evaluated the significance of SIMs in intrahepatic recurrence (IHR) of early‐stage HCC after curative treatment. This study was performed using prospectively collected registry data of newly diagnosed, previously untreated HCC between 2005 and 2017 at a single institution. Inclusion criteria were patients with Barcelona Clinic Liver Cancer stage 0 or A, who underwent curative treatment. Pre‐treatment and post‐treatment values of platelet, neutrophil, lymphocyte, monocyte, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) were analyzed with previously well‐known risk factors of HCC to identify factors associated with IHR‐free survival (IHRFS), early IHR, and late IHR. Of 4076 patients, 2142 patients (52.6%) experienced IHR, with early IHR in 1018 patients (25.0%) and late IHR in 1124 patients (27.6%). Pre‐treatment platelet count and PLR and post‐treatment worsening of NLR, PLR, and LMR were independently associated with IHRFS. Pre‐treatment platelet count and post-treatment worsening of NLR, PLR, and LMR were significantly related to both early and late IHR. Pre-treatment values and post‐treatment changes in SIMs were significant factors of IHR in early‐stage HCC, independent of previously well‐known risk factors of HCC.
AB - Systemic inflammatory markers (SIMs) are known to be associated with carcinogenesis and prognosis of hepatocellular carcinoma (HCC). We evaluated the significance of SIMs in intrahepatic recurrence (IHR) of early‐stage HCC after curative treatment. This study was performed using prospectively collected registry data of newly diagnosed, previously untreated HCC between 2005 and 2017 at a single institution. Inclusion criteria were patients with Barcelona Clinic Liver Cancer stage 0 or A, who underwent curative treatment. Pre‐treatment and post‐treatment values of platelet, neutrophil, lymphocyte, monocyte, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) were analyzed with previously well‐known risk factors of HCC to identify factors associated with IHR‐free survival (IHRFS), early IHR, and late IHR. Of 4076 patients, 2142 patients (52.6%) experienced IHR, with early IHR in 1018 patients (25.0%) and late IHR in 1124 patients (27.6%). Pre‐treatment platelet count and PLR and post‐treatment worsening of NLR, PLR, and LMR were independently associated with IHRFS. Pre‐treatment platelet count and post-treatment worsening of NLR, PLR, and LMR were significantly related to both early and late IHR. Pre-treatment values and post‐treatment changes in SIMs were significant factors of IHR in early‐stage HCC, independent of previously well‐known risk factors of HCC.
KW - hepatocellular carcinoma
KW - intrahepatic recurrence
KW - lymphocyte‐to‐monocyte ratio
KW - neutrophil‐to‐lymphocyte ratio
KW - platelet‐to‐lymphocyte ratio
KW - systemic inflammatory marker
UR - http://www.scopus.com/inward/record.url?scp=85128520759&partnerID=8YFLogxK
U2 - 10.3390/cancers14092081
DO - 10.3390/cancers14092081
M3 - Article
AN - SCOPUS:85128520759
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 9
M1 - 2081
ER -